What Is Autosomal Dominant Alzheimer’s Disease?

A clear look at the three genes behind inherited early-onset Alzheimer's, why onset runs in families, and what carriers can actually do now.

Autosomal dominant Alzheimer's disease (ADAD) is a rare, inherited form of Alzheimer's caused by a mutation in one of three genes — *APP*, *PSEN1* or *PSEN2*. "Autosomal dominant" means a single inherited copy of the mutation is enough to cause the disease, so each child of a carrier has a 50% chance of inheriting it and, if they do, of developing Alzheimer's — usually decades earlier than the typical late-life form.

This is not the same as the gene variants that merely raise Alzheimer's risk, such as *APOE4*. ADAD is deterministic: carriers develop symptoms, and the age at which they do tends to run in the family. That predictability is painful for families, but it has also made them central to the most promising prevention research in the field.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

How the inheritance works

Autosomal genes come in pairs, one copy from each parent. In a dominant condition, the mutated copy overrides the healthy one. A parent who carries an ADAD mutation therefore passes it to roughly half their children, and sons and daughters are affected equally.

The three genes all sit on the same biological pathway. *APP* encodes amyloid precursor protein; *PSEN1* and *PSEN2* encode presenilins, the enzymes that cut it. Mutations shift that cutting toward longer, stickier amyloid-beta fragments, which accumulate in the brain years before memory changes appear. According to a genetic counseling and testing review published in PMC, a single inherited copy is sufficient to cause disease — which is why there is usually a visible chain of affected relatives across generations, rather than a single isolated case.

How rare is it?

ADAD accounts for a very small share of Alzheimer's overall. Early-onset Alzheimer's — symptoms before about age 65 — makes up roughly 1–5% of all Alzheimer's cases, and only about 10% of those early-onset cases follow an autosomal dominant inheritance pattern, per a synopsis of Alzheimer's genetics in PMC. The three genes are not equally involved.

*PSEN1* is mutated most often, *APP* next, and *PSEN2* is rarest, appearing in under 1% of early-onset cases. Even taken together, the three genes explain only 18–50% of autosomal dominant early-onset families — meaning some families with a clear dominant pattern still get no genetic answer from current testing. The mutations themselves are also varied rather than a short recurring list. A 2025 analysis in *Brain* catalogued 550 distinct variants across the three genes, so a family's mutation is often one seen in only a handful of people worldwide.

When symptoms start, and how they differ

Onset in ADAD arrives decades earlier than in sporadic Alzheimer's, and the gene involved shapes the timing. A molecular diagnosis study indexed in PubMed reported mean onset around 41.7 years for *PSEN1* carriers versus 51.2 years for *APP* carriers, with reported ranges running from the mid-20s to the 60s. Within a single family, onset age clusters tightly — often within a few years of an affected parent's or sibling's age at diagnosis.

Clinicians use that family history as a rough planning anchor, though it is an average, not a date. Because carriers are young and working, the practical consequences differ from late-onset disease. Employment, dependent children, mortgage and insurance decisions, and the need for a workplace accommodation all arrive at once, and symptoms may first be mistaken for burnout, depression, or stress.

What research in these families has shown

Predictable onset makes ADAD families uniquely informative, which is why they are followed as a prevention cohort through the Dominantly Inherited Alzheimer Network (DIAN) at Washington University and its treatment arm, DIAN-TU. Researchers can start a drug in people who are still symptom-free but have a known onset window. The first trial did not work.

DIAN-TU-001, a double-blind study, tested solanezumab (Eli Lilly) and gantenerumab (Roche); both missed the primary cognitive endpoint when results were reported in 2020. The open-label extension was more encouraging. Published in *The Lancet Neurology* in 2025, it found that long-term anti-amyloid treatment in carriers who were still symptom-free was associated with roughly a 50% lower risk of going on to develop symptoms, as summarized by WashU Medicine.

How much weight that 50% figure can carry

Not as much as the headline suggests. *Lancet Neurology* commentators called the result "statistically inconclusive." The specifics behind that judgment matter for anyone weighing their options: A result this small and this unblinded is a reason to keep studying the approach, not a basis for treating outside a trial. It is also worth noting that gantenerumab's development program was discontinued, so the specific drug behind the finding is no longer moving toward approval.

  • The 50% figure comes from an exploratory, unblinded subgroup of only 22 participants.
  • It sits against a null primary trial result, not a positive one.
  • ARIA — amyloid-related imaging abnormalities, meaning brain swelling or microbleeds — occurred in 30% of extension participants versus 19% in the original trial, attributed to the higher dosing used in the extension.

Practical next steps for a family at risk

There is no approved preventive therapy for ADAD carriers today. What is available is information and access to research, in that order. Testing negative for a known family mutation means the ADAD risk is gone — but ordinary, age-related Alzheimer's risk remains the same as anyone else's, which is worth hearing clearly from a counselor rather than inferring it.

  • **Start with genetic counseling, before testing.** A counselor maps the family history, confirms whether a dominant pattern is actually present, and works through what a positive or negative result would change — insurance, disclosure to relatives, family planning. Predictive testing in an unaffected adult is irreversible knowledge.
  • **Get the affected relative tested first, where possible.** Identifying the family's specific variant makes testing other relatives far more informative, which matters given that current genes explain only part of dominant families.
  • **Ask about trial enrollment.** DIAN-TU runs a current prevention platform trial, registered as NCT06424236, which is the main route to investigational preventive treatment for carriers.
  • **Plan on the family's timeline, not the general population's.** With onset averaging in the early 40s for *PSEN1* carriers, advance directives, powers of attorney, disability coverage and care planning belong in a carrier's 30s.

Frequently Asked Questions

Does a negative *APP*/*PSEN1*/*PSEN2* test rule out inherited Alzheimer's in my family?

Not entirely. The three known genes account for only 18–50% of autosomal dominant early-onset families, so a family with a clear inheritance pattern can still test negative on all three.

Is *APOE4* the same thing as an ADAD mutation?

No. *APOE4* raises risk without determining outcome, while an ADAD mutation in *APP*, *PSEN1* or *PSEN2* causes the disease in carriers who live to their family's onset age.

Can I take an approved anti-amyloid drug as prevention if I carry a mutation?

No preventive therapy is approved for carriers, and gantenerumab's program — the drug behind the 2025 extension result — was discontinued. DIAN-TU's platform trial is the route to investigational treatment.

Why do these families get so much research attention?

Because onset age is largely predictable within a family, researchers can begin treatment in people who are still symptom-free and measure whether symptoms are delayed — something far harder to do in sporadic Alzheimer's.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.